Quick Answer
CHINA PHARMA HOLDINGS, INC. reported Operating Income Loss of -$4.59 million for the year ending 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -66.8% in Operating Income Loss from 2023 to 2024.
- This data is from CHINA PHARMA HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2010 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2010 to 2024), CHINA PHARMA HOLDINGS, INC.'s Operating Income Loss has declined by 118.6%.
- Historical annual values: Fiscal year 2024: -$4.59 million | Fiscal year 2023: -$2.75 million | Fiscal year 2022: -$3.55 million | Fiscal year 2021: -$2.86 million | Fiscal year 2020: -$2.58 million | Fiscal year 2019: -$20.41 million | Fiscal year 2018: -$10.45 million | Fiscal year 2017: -$18.68 million | Fiscal year 2016: -$8.16 million | Fiscal year 2015: -$14.30 million | Fiscal year 2014: -$38.76 million | Fiscal year 2013: -$18.61 million | Fiscal year 2012: $5.91 million | Fiscal year 2011: $22.03 million | Fiscal year 2010: $24.66 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: